Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

n patients with chronic gout who will receive allopurinol.  Given the low response rate typically observed with allopurinol and its well established side effect profile, we expect a substantial number of patients from these studies will be eligible to enroll directly into our Phase 3 studies.  
  • During the third quarter of 2011, we expect to report the results of an "End of Phase 2" meeting with the FDA for lesinurad.
  • Our next generation URAT1 inhibitor for gout, RDEA3170, has received regulatory approval for Phase 1 dosing, which we expect will commence in the third quarter of 2011.

  • Second Quarter and Year-to-Date 2011 Financial ResultsAs of June 30, 2011, we had $141.3 million in cash, cash equivalents and short-term investments and $1.7 million in receivables, compared to $80.6 million in cash, cash equivalents and short-term investments and $17.0 million in receivables as of December 31, 2010.

    The net increase in cash, cash equivalents and short-term investments in 2011 was due primarily to our public offering of common stock, which was completed in February 2011 and resulted in net proceeds to us of $78.1 million, and the receipt in January 2011 of a $15.0 million milestone payment under our global license agreement with Bayer HealthCare (Bayer).  These increases were partially offset by the use of cash to fund our clinical-stage programs, personnel costs and for other general corporate purposes.  The decrease in receivables in this period was due to the receipt of the $15.0 million milestone payment from Bayer.

    Revenues totaled $2.2 million and $3.9 million for the three and six months ended June 30, 2011, respectively, and $3.5 million and $6.8 million for the three and six months ended June 30, 2010, respectively.  The revenue earned in 2010 and 2011 was primarily from the recognition of a portion of the $35.0 million upfront, non-refundable license fee and reimbursement of third
    '/>"/>

    SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Ardea Biosciences to Present at Upcoming Investor Conferences
    2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
    3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
    4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    6. Ardea Biosciences Prices Public Offering of Common Stock
    7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... announced that it has commenced an underwritten public offering ... grant the underwriters a 30-day option to purchase up ... common stock offered in the public offering. The offering ... no assurance as to whether or when the offering ...
    (Date:4/30/2015)... , April 30, 2015 The following is ... of Directors of China Cord Blood Corp (NYSE: CO ... special committee of the independent directors of China Cord Blood ... privatization offer of $6.40 per share from Golden Meditech Holdings ... $6.40 per share would greatly benefit Golden Med and Mr. ...
    (Date:4/30/2015)... , April 30, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics including high ... the closing of its previously announced underwritten public ... at a public offering price of $15.50 per ... the underwriters of their option to purchase up ...
    (Date:4/30/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... provider, today announced that its board of directors has ... 2015, from a consortium (the "Consortium") led by Dr. ... chief executive officer of the Company, and Ally Bridge ... "Transaction") involving the acquisition of all outstanding shares of ...
    Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
    ... Genetics, the parent company of Myeloma Health, a privately ... announced the formation of their Scientific Advisory Board. They ... Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer ... Medical School Dr. Anderson of Dana-Farber Cancer ...
    ... AutoGenomics, a leader in providing automated, molecular testing solutions ... the U.S. Food and Drug Administration to market its ... *2, *3, *17, of the CYP450 2C19 gene and ... testing platform, the INFINITI® Analyzer.   "We ...
    ... ("China-Biotics", the "Company") (Nasdaq: CHBT ), the ... China, today announced it will host a conference call ... Beijing Time on Tuesday, November 9, 2010, to discuss ... financial results for the period ended September 30, 2010. ...
    Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3AutoGenomics Receives FDA Clearance for its INFINITIĀ® CYP2C19 Assay 2China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9 2
    (Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
    (Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
    (Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
    Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
    ... Science Research Conference on focuses on recent advances in ... transcriptional regulators, currently numbering 17, and will also include ... Held twice previously, this FASEB Conference is the ... The major themes of the conference will be the ...
    ... medicine? The media are invited to register now for ... Clinical Genetics Meeting, March 25-29, 2014 at the Nashville ... Sequencing to Cancer Genetics, the focus of the ACMG ... genomics in healthcare, showcasing the latest breakthroughs in genetics ...
    ... European consortium of epilepsy researchers has reported the discovery ... Using a novel combination of technologies, including trio exome ... tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found ... a subset of epilepsy patients with symptoms similar to ...
    Cached Biology News:Complimentary press registration now open for ACMG 2014 Annual Clinical Genetics Meeting 2European epilepsy consortium identifies new gene for severe childhood epilepsy 2European epilepsy consortium identifies new gene for severe childhood epilepsy 3European epilepsy consortium identifies new gene for severe childhood epilepsy 4
    Polyclonal Antibody to PRG3...
    Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
    Mouse monoclonal [2991] to C3a / C3a des Arg ( Abpromise for all tested applications). SwissProtID: P01024...
    Polyclonal Antibody to SHPRH...
    Biology Products: